Last updated on December 2016

Pilot BA Study of New LY03005 vs Pristiq

Brief description of study

The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

Detailed Study Description

Twenty (20) eligible subjects will be enrolled and assigned to either LY03005 group or Pristiq group at a 1:1 ratio at one site in the USA.

Clinical Study Identifier: NCT02988024

Find a site near you

Start Over

Clinilabs, Inc.

Eatontown, NJ United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.